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Abstract
Background: The primary goal of current chemotherapy in hepatoblastoma (HB) is reduction of tumour volume
and vitality to enable complete surgical resection and reduce risk of recurrence or metastatic disease. Drug
resistance remains a major challenge for HB treatment. In some malignancies inhibition of anti-apoptotic pathways
using small BH3 mimetic molecules like ABT-737 shows synergistic effects in combination with cystotoxic agents in
vitro. Now we analysed toxicology and synergistic effects of this approach in HB cells and HB xenografts.
Methods: Viability was monitored in HB cells (HUH6 and HepT1) and fibroblasts treated with paclitaxel, ABT-737
and a combination of both in a MTT assay. HUH6 xenotransplants in NOD/LtSz-scid IL2Rgnull mice (NSG) were
treated accordingly. Tumour volume and body weight were monitored. Xenografted tumours were analysed by
histology and immunohistochemistry (Ki-67 and TUNEL assay).
Results: ABT-737 reduced viability in HUH6 and HepT1 cells cultures at concentrations above 1 μM and also
enhanced the cytotoxic effect of paclitaxel when used in combination. Thereby paclitaxel could be reduced tenfold
to achieve similar reduction of viability of tumour cells. In contrast no toxicity in fibroblasts was observed at the
same regiments. Subcutaneous HB (HUH6) treated with paclitaxel (12 mg/kg body weight, n = 7) led to delayed
tumour growth in the beginning of the experiment. However, tumour volume was similar to controls (n = 5) at
day 25. Combination treatment with paclitaxel and ABT-737 (100 mg/kg, n = 8) revealed significantly 10 fold lower
relative tumour volumes compared to control and paclitaxel groups. Paclitaxel dependent toxicity was observed in
this mice strain.
Conclusions: Our results demonstrate enhancement of chemotherapy by using modulators of apoptosis. Further
analyses should include improved pharmacological formulations of paclitaxel and BH3 mimetics in order to reduce
toxicological effects. Sensitising HB to apoptosis may also render resistant HB susceptible to established
chemotherapy regimens.
Background
Treatment results of children suffering from hepatoblas-
toma (HB) have been improved impressively during
recent years. Current treatment strategies include
neoadjuvant chemotherapy regimens and surgery in
standard risk HB, achieving a 3-year overall survival
probability of 96% [1-4]. However, the outcome of
patients with high risk HB and relapsed HB (3-year sur-
vival: 69%) is still poor.
To improve outcome, therapy has been intensified
using second-line cystostatic drugs in the standard treat-
ment protocol for high risk HB [2]. Paclitaxel is mainly
used in treatment regimes for ovarian, breast and non-
small cell lung cancer. It has also been applied in pae-
diatric patients with refractory malignancies and has
been proposed as potential agent against high risk HB
[5-9]. Paclitaxel stabilizes microtubules and as a result,
interferes with the normal breakdown of microtubules
during cell division [10]. This mitotic inhibitor promotes
apoptosis as a secondary effect.
Apoptosis is an important factor in anticancer treat-
ment and targeting this cell death mechanism has been
constituted a promising alternative treatment option.
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cules encoded by genes of the Bcl family [11,12]. Bcl-2,
an important member of this family, blocks cytochrome
C release by sequestering pro-apoptotic BH3-only pro-
teins such as tBid, Bad, Bax, and Bim. Bcl-2 overexpres-
sion plays a central role in resistance to chemotherapy
in multiple malignancies including HB [13]. Small BH3
mimetic molecules facilitate the activation of pro-apop-
totic Bcl proteins by binding to the hydrophobic groove
in Bcl-2 and Bcl-XL thus sensitizing tumour cells for
apoptosis [14]. One of these molecules, ABT-737, was
developed as an anti-tumour agent, induces apoptosis by
selectively inhibiting the anti-apoptotic proteins Bcl-2,
Bcl-XL, and Bcl-W. ABT-737 as a single agent has
shown activity against several hematopoietic cell lines
(leucaemias, multiple myeloma and cultured lymphoma)
and some solid tumour cell lines, whereas efficiency was
high in small cell lung carcinoma only [15-19]. Because
ABT-737 does not block Mcl-1, it is anticipated that
this drug will be most effective as a single agent against
tumours that express low levels of these pro-survival
protein [20]. Thus, ABT-737 may be active also in HB
tumours, as gene expression analysis revealed a 2-fold
lower expression of Mcl-1 in native HB tissue than in
normal liver tissue [21]. Highly synergistic in vivo effects
have been described when combining ABT-737 with
established chemotherapeutic drugs [15,22]. In HB cells
ABT-737 also induces apoptosis and enhances the effect
of cytotoxic drugs (DOXO (doxorubicin), CDDP (cispla-
tin), paclitaxel and etoposide) commonly used in treat-
ment protocols of HB [12].
I nt h i ss t u d yw ed e s c r i b et he effects of ABT-737 in
combination with paclitaxel in HB xenografts.
Methods
Drugs
ABT-737 and its enantiomer were kindly provided by
Abbott (Abbott GmbH & Co. KG, Wiesbaden, Ger-
many). For in vitro studies ABT-737 and its enantiomer
w e r ed i s s o l v e di nD M S Oa t1m Ma n dd i l u t e dw i t h
medium to a final concentration in the cell culture of
0.01, 0.1, 0.3, and 1 μM. For animal studies ABT-737
was slowly dissolved in a mixture consisting of 30% pro-
pylene glycol, 5% Tween80 and 65% dextrose in water.
The vehicle was brought to a pH of 1.0 by adding 5 mol
HCL to enable the compound to go into solution sup-
ported by sonication. After the compound was in solu-
tion, the pH was slowly raised to 3-4 by addition of
aqueous NaOH. Paclitaxel was provided by Neocorp AG
(Weilheim, Germany).
Cells and culture conditions
The HB cell lines HepT1 [23] and HUH6 [24] were used
for all experiments. The cells were transduced with a
plasmid encoding gaussia luciferase (GLuc, pCMV-GLuc,
NEB, Frankfurt am Main, Germany). Stable clones were
isolated and maintained in DMEM (GIBCO BRL, Carlsbad,
CA) supplemented with 10% FCS and G418. Tumour cells
were grown as monolayer in Dulbecco’s MEM medium
(Biochrom, Berlin, Germany) supplemented with 10% fetal
calf serum, 1% glutamine, and 2,5% HEPES buffer (Gibco,
Eggenstein, Germany). The cells were grown at 37°C in a
humidified atmosphere containing 5% carbon dioxide. All
used cells were mycoplasma negative.
Fibroblasts were derived from human skin samples by
tissue culture and grown as monolayer in the first three
passages as described for tumour cells.
Cell viability assay
HB cells (10,000 cells/100 μl) were seeded out in 96-well
plates (Becton Dickinson GmbH, Heidelberg, Germany)
and cultured as described above. At day two, paclitaxel
was added to the cells at 7 different concentrations
around IC50 [13]. ABT-737 was added to a final concen-
tration in the cell culture of 0.01, 0.1, 1, and 3 μM.
Experiments were repeated with fibroblasts and ABT-737
alone, as well as with ABT-737 combined with paclitaxel.
Drug diluents were prepared shortly before administra-
tion. All assays were performed 3 times in quadruplicates.
Cell viability was assessed by MTT [3-(4.5-
dimethylthiazol-2-yl)-2.5-diphenyl-tetrazoliumbromide]-
assay (Sigma-Aldrich, Munich, Germany). 25 μl MTT (5
mg/ml) dissolved in PBS was added to each well. After
incubation for 3 hours 100 μl/well lysis solution (10%
SDS in acid water; Merck, Darmstadt, Germany) was
added and further incubated over night in the dark at
room temperature. Cell viability was assessed by mea-
suring absorption at 570 nm using a Milena Kinetic
Analyzer (DPC Bierman, Bad Nauheim, Germany). Per-
centages of cell viability were calculated by normaliza-
tion of culture background without cells against
untreated cultures as control. Dose dependent viability
curves were computed by sigmoidal curves with variable
slope to determine IC50.
Apoptosis assay
For detecting apoptosis, the active caspase 3 assay was
performed using Caspase-Glo™ 3/7 Assay according to
the manufactory instructions (Promega, Mannheim,
Germany). Briefly, 104 cells were seeded into a 96-well
plate. After 24 h, the cells were treated with paclitaxel
(0.1 and 0.3 μg/ml) and ABT-737 (0.3 μM). After treat-
ment, the cells were harvested in Caspase substrate and
luminescence was recorded for 10 seconds.
Animals and Xenotransplantation
Xenotransplantation was performed as previously
described [25]. All animal studies were approved by the
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ments. (Regierungspräsidium Tübingen, Fachgebiet
Tierschutz, Number K3/10). HUH6 cells were injected
into the flank of 6-8 weeks old NOD/LtSz-scid IL2Rg-
null mice (NSG). Animals were held under pathogen
free conditions and were fed ad libitum with autoclaved
food and sterilized water. For each tumour 0.2 ml of
tumour cell suspension (2 × 10
6 cells) was injected sub-
cutaneously into paravertebral areas. The observation
time was 4 weeks, each group consisted of 6-8 animals.
Treatment was initiated when tumours had reached a
length of 5 mm. Paclitaxel in 200 μl saline solution was
administered i.p. once per day on days 1-4 and 15-18
with a dosage of 12 mg/kg bodyweight. ABT-737 was
administed i.p. with a dosage of 100 mg/kg bodyweight
alone or in combination with paclitaxel using the same
schedule. Drugs were prepared immediately prior to
administration. Control animals were left untreated till
day 25 unless tumour volume exceeded 1.5 cm
3.
Tumour volumes (V = 4/3π × a/2 × b/2 × c/2) and
body weight of all animals were determined every 5
days. Relative tumour growth was calculated as a pro-
portion of tumour volumes at each time point compared
to day 0. Blood samples were taken from the retrobulbar
plexus on days 0, 14, and 25. Serum GLuc activity was
quantified in fresh serum. Therefore, 5 μls e r u mw a s
added to 50 μl Gaussia GlowJuice (J.P.K. Instruments
AG, Berlin, Germany) and GLuc activity was measured
using a luminometer (Magic
® Lite Analysator, Ciba
Corning) after adding 1 μl coelenterazine 100 μMt o
acquire photon counts for 10 sec. Activity was expressed
as relative light units per second (RLU/s). Tumours
were explanted on day 25 and prepared for histological
analysis.
Histology and Immunohistochemistry
Paraffin embedded sections obtained from xenografted
tumours and liver were used for immunohistochemical
staining against Ki-67. For each group 3 sections were
cut (10 μm) from 4-5 different paraffined tumour blocks
and mounted onto SuperFrost
® Plus microscope slides
(R. Langenbrinck, Emmendingen, Germany). Sections
were fixed and dehydrated using graded alcohol. The
endogenous peroxidase activity was blocked by adding
0.03% Peroxidase (Merck, Darmstadt, Germany) for 10
min. Unspecific binding sites were blocked by incuba-
tion with phosphate buffered saline (PBS) containing
0.1% Tween 20 (PBST) (Sigma Aldrich, Munich, Ger-
many) and 1% goat serum (Dako, Carpinteria, CA, USA)
for 30 min. Sections were incubated with monoclonal
mouse anti-human Ki-67 antibody (1:400; Dako) over
night. Polyclonal rabbit anti-rat IgG antibody (1:100 bio-
tin-labeled; Biozol, Eching, Germany) was used as
secondary antibody. Avidin-biotin-peroxidase-complex
(ABC) and DAB staining was applied using ABC-Kit
PK-6100 standard (Linaris, Wertheim, Germany) accord-
ing to manufacturer’s protocol. Positively dividing cells
were stained brown. For nuclear staining sections were
counterstained in Mayer’sH a e m a l a u ns o l u t i o nf o r3 0
sec. The proliferation index (PI) was calculated through
division of the number of Ki-67 positive cell nuclei by
the number of all tumour cells per high power field
(20×). PI was given as mean of 3 randomly evaluated
regions for all tumour samples. Sections were also
stained using standard Mayer’s Haemalaun as well as
Eosin G-dilution and were analyzed by microscopy
(Axioscope 40; Carl Zeiss, Oberkochen, Germany).
TUNEL assay
Apotosis in explanted tumour tissue was assessed using
TUNEL assay (Roche, Mannheim, Germany) according
to the manufacturer’s guidelines. Cells positive for apop-
tosis showed a green fluorescent signal and were visua-
lized by fluorescence microscopy using a Zeiss Axio
Scope epifluorescence microscope (Carl Zeiss GmbH,
Oberkochen, Germany) and AxioVision software 3.1
(Carl Zeiss Vision, Aalen, Germany).
Statistical analysis
Statistical analysis of relative tumour growth and body
weights at distinct time points was carried out by one
way ANOVA followed by Dunns’ multiple test using
GraphPad Prism 4.00 (GraphPad Software, San Diego,
Califonia, USA, http://www.graphpad.com). Viability
curves and tumour growth were fitted with a sigmoidal
dose response function with variable slope. F-Test was
used to compare curve parameters of treatment with
and without ABT-737. All numeric data were expressed
as means. Data plotted on graphs represent means and
SD. Significance was assumed for all p < 0.05.
Results
Synergistic effect of paclitaxel and ABT-737 on HB cells
ABT-737 enhances the effect of various cytotoxic drugs
in a combination treatment of tumour cell lines. To
determine effects of treatment on HB cells a MTT assay
was done. Paclitaxel alone led to a decreased viability in
HepT1 and HUH6 cells (Figure 1A, B). IC50 of paclitaxel
were 1 μg/ml in HepT1 cells and 6 μg/ml in HUH6
cells. Paclitaxel in combination with ABT-737 showed
synergistic effects and considerable decrease of viability
in HB cells. Combined paclitaxel (0.1 μg/ml)/ABT-737
(0.3 μM) treatment reduced cell viability in HepT1 cells
to 50%. Treatment results were even more impressive in
HUH6 cells. In this cell line only 25% of cells were vital
after treatment with 0.01 μg/ml paclitaxel plus 0.3 μM
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combination with paclitaxel at 1 μg/ml did not reduce
the viability of HB cells under 50% of a control (data
not shown). In contrast, fibroblasts showed a dose-inde-
pendent constant viability approximately 80% after treat-
ment with paclitaxel alone and of approximately 75%
after treatment with paclitaxel plus ABT-737. Paclitaxel
induced apoptosis in HB cells as detected by quantifying
Caspase 3 activity. In HUH6 cells a fourfold increase of
Caspase 3 activity was detected when ABT-737 was
added to paclitaxel. In HepT1 cells a higher background
activity was observed compared to HuH6 cells and Cas-
pase 3 activity was only slightly enhanced by paclitaxel
or combination treatment (Figure 1C).
Treatment of HB-xenografts with a combination of
paclitaxel and ABT-737
HUH6 xenografts were used to describe effects of ABT-
737 in combination with paclitaxel in vivo. All xeno-
transplantated animals developed measurable tumours
after 4-5 weeks. As an additional control parameter,
expression of the transgene GLuc was detected in the
blood of all mice at levels above 200 RLU/s, attesting
tumour development. Tumour volume increased con-
stantly in the control group (n = 5) (Figure 2A). A simi-
lar growth curve was observed in the group treated with
ABT-737 alone (n = 5). Treatment with paclitaxel
(n = 7) alone led to delayed tumour growth in the
Figure 1 Synergistic effect of paclitaxel and ABT-737 cultured
cells. Fibroblasts (black square), HepT1 (black triangle) and HuH6
(black rhomb) cells were incubated with paclitaxel at seven different
concentrations alone (A) and in combination with 0.3 μM ABT-737
(B). Relative cell viability was determined 72 hrs later in a MTT assay.
No toxicity was observed in fibroblasts. For HB cells synergistic
effects of combined treatment could be observed. Apoptosis was
detected by Caspase 3 activity 24 h after combination treatment of
HuH6 and HepT1 cells (C). Enhanced Caspase 3 activity was found
in HuH6 cells incubated with paclitaxel and 0.3 μM ABT-737 when
compared with paclitaxel alone.
Figure 2 Tumour growth after treatment with paclitaxel alone
and in combination with ABT-737.( A) HuH6 derived s.c. tumours
were treated with paclitaxel (white triangle), ABT-737 (black square),
and with a combination of both (black triangle) at indicated time
points. Untreated animals served as controls (white square). Data
points indicate means and SD of tumour volumes at respective
days. (B) After the first cycle of treatment (14 days) the combination
of paclitaxel and ABT-737 revealed a significantly lower relative
tumour growth compared to controls and paclitaxel treated
tumours. Data represent the relative tumour volume of each animal.
*p < 0.05 in a Student t-test.
Lieber et al. BMC Cancer 2011, 11:362
http://www.biomedcentral.com/1471-2407/11/362
Page 4 of 8beginning of the experiment, but reached the mean
tumour volume of the control group at day 25. Com-
bined treatment of paclitaxel and ABT-737 (n = 8) did
not show significant increase of tumour volume. In the
first treatment cycle 3 animals of this group died. The
remaining 5 animals died in the second cycle of treat-
ment. Statistical analysis of tumour volumes between
groups after completion of the first treatment course
revealed significant lower relative tumour volume in the
combined treatment group compared to control group
and ABT-737 group (Figure 2B). Student t-test revealed
a significant enhanced treatment efficiency of paclitaxel
in combination with ABT-737 compared to paclitaxel
alone (p = 0.01).
Immunhistological analysis of HB xenografts of the
control group and paclitaxel group showed high density
of tumour cells in HE staining (Figure 3). In contrast,
multiple picnotic cells, hemorrhagic infarction, and large
areas of necrosis were seen in the tumours of the com-
bined treatment group. Brown staining of cells marked
by anti-Ki-67 revealed dividing tumour cells. Cell prolif-
eration was high in control tissues (PI 309 ± 109).
Lower proliferation was observed in tumours treated
with paclitaxel (PI = 233 ± 67) and ABT-737 (PI = 292
± 38). Combination of both drugs further reduced pro-
liferation (PI = 164 ± 21).
Apoptosis was detected by TUNEL assay. Thereby
green fluorescent cells showed DNA fragmentation. The
highest amount of apoptotic cells was seen in tumours
after combined paclitaxel/ABT-737 treatment. Only in
this group large areas of disintegrated tumours were
detected. In summary, additive effects after paclitaxel
and ABT-737 treatment were demonstrated in HB xeno-
grafts assessing tumour growth and histological
appearance.
Toxicity of paclitaxel in NSG mice
Toxicity was monitored by changes of body weight dur-
ing treatment. Tumour bearing mice gained weight or
remained constant during the 4 days of a treatment
cycle (Figure 4A). Significant loss of 10% body weight
was observed in the groups treated with paclitaxel or
paclitaxel/ABT-737 compared with control animals (one
way anova, p < 0.01). In the group treated with com-
bined paclitaxel/ABT-737, 3 animals died in the first
treatment cycle. The remaining 5 animals regenerated in
the following 10 days, but died during the second cycle.
Treatment with paclitaxel led to toxicity related death in
1 of 7 mice. Others showed general apathy. During
necropsy no macroscopic tissue and organ changes were
observed. No toxcitiy was observed after treatment with
ABT-737 alone. Histological analysis of liver tissue after
combined treatment with paclitaxel and ABT-737
detected islands of piknotic cell nuclei in HE staining at
the timepoint of death (Figure 4B-E). In contrast, liver
tissue of the control group and animals treated with
paclitaxel or ABT-737 alone, did not show such changes
of histological morphology at the end of the experiment
(day 25).
Figure 3 Immunhistological analysis of HB tumours.I m a g e s
show staining of Haematoxilin and Eosin (A-D), detection of Ki-67
(E-H) and Tunel assay (I-L). For each representative samples of
controls (A, E, I), paclitaxel (B, F, J), ABT-737 (C, G, K) and
combination (D, H, L) are provided. Combined treatment using
paclitaxel and ABT-737 reveals high tissue damage and a low
proliferation index. Multiple picnotic nuclei denote necrotic tissue
destruction. Brown staining shows Ki-67 positive cells. Bright green
fluorescences are apoptotic cells. Nuclear staining was done by
Hematoxylin and DAPI, respectively.
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Survival for children with HB is linked to complete
resection of the primary tumour, which is possible in
fewer than 50% of cases [1-3,26]. Chemotherapy plays
an essential role in the treatment of HB by reducing
extension of primarily unresectable tumours [1,2]. How-
ever, multi drug resistance develops in 80% of initially
CDDP and DOXO sensitive patients after 4-5 courses
of chemotherapy and remains a challenge in the optimi-
zation of treatment strategies. For high-risk and
relapsed HB-characterized by complex drug resistance-
various cytotoxic agents are used that have shown
encouraging preclinical results as second line treatment
in some interventional trials. Paclitaxel has proven effi-
ciency in the treatment of HB cells in vitro and in
xenotransplanted HB and has been proposed for the
treatment of pediatric refractory malignancies [5,6,12].
In our study an initial tumour response to paclitaxel
mono therapy was observed in xenografts. However, at
the end of the observation time, tumours began to re-
grow. Several mechanisms are currently under investiga-
tion in order to improve efficiency of chemotherapeutic
agents [27].
One of them is modulation of apoptosis using small
BH3 mimetic molecules, such as ABT-737, obatoclax,
TW-37 and HA14 [14]. ABT-737 induces apoptosis as a
single drug when treating various cell lines including
HB in vitro and has previously shown additive effects
when combined with various cytotoxic drugs including
paclitaxel [12,15,17,22,28]. We observed additive effects
of the combined therapy using paclitaxel and ABT-737
in a xenograft HB model, resulting in inhibition of
tumour growth. Similar to our findings, CDDP reduced
tumour growth when used alone but was more effective
in some HB xenografts when combined with inhibitors
of multi drug resistant proteins [25,29]. However, in this
case the inhibitor targeted a putative induced expression
of a particular drug resistant protein, which is also
expressed in various normal tissues. In this study we
used an inhibitor of an apoptosis modulating protein,
thereby enhancing the tumour sensitivity to other drugs
without compromising normal cells.
Paclitaxel is well tolerated in adults and children with
some refractory or progressive solid tumours showing
acceptable minor toxicity [30,31]. However, dose-depen-
dent neurotoxicity and some local toxic effects such as
abdominal pain after treatment with paclitaxel, which is
rapidly cleared by the liver, have also been described
[32,33]. In this study, toxicity of paclitaxel in NSG mice
was observed. Other authors described no discernable
increased toxicity, but used athymic NCr-nu ⁄ nu nude
mice rather than NSG mice in their xenograft experi-
ments [34,35]. The more resistant strains such as NMRI
Figure 4 Toxicity of paclitaxel in NSG mice.N S Gm i c ew e r e
treated as indicated on 4 consecutive days. The body weight is
shown as fraction for each individual mouse at day 5 and at the
beginning of the experiment (A). Significant loss of 10% body
weight was observed in the groups treated with paclitaxel (black
circle) and paclitaxel/ABT-737 (black triangle) compared with control
(black rhomb) animals (one way Anova, Dunnett’s multiple test p <
0.01). HE staining of liver tissues revealed multiple picnotic cells after
combination treatment (E), which were not found in the other 3
groups: control (B), paclitaxel (C) and ABT-737 (D).
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lower HB incidence after xenotransplantation [36].
Some pharmacological properties of paclitaxel were
changed in previous studies by chemical derivation and
liposomal formulation in order to reduce liver toxicity.
Docetaxel, a semi-synthetic analogue of paclitaxel also
leading to tumour regression, was described without
significant toxicity in athymic NMRI mice [37]. The
concept of reducing toxic effects by combining che-
motherapeutics with natural compounds, such as beta-
1,3-D-glucan, is very compelling, since some hepatotoxic
side effects have finally been reported, even though
higher paclitaxel dosage were used than in our study
[38]. In addition, lyophilized paclitaxel magnetolipo-
somes demonstrated to be effectively delivered to the
tumour and exert significant anticancer activity with
fewer side effects when administrated parenterally in a
xenograft mouse model for breast carcinoma [39]. How-
ever, we used paclitaxel in our study for a better com-
parability, since this agent had been used in previous
studies of HB as well. Nevertheless, formulations with
improved pharmacological properties might be more
suitable for testing cytotoxic agents in NSG mice.
In contrast to paclitaxel, ABT-737 alone (100 mg/kg
bodyweight) was not associated with toxic effects in this
and other studies [15,22]. But when combining pacli-
taxel and ABT-737, toxicity was even higher than after
treatment with paclitaxel alone. Treatment with pacli-
taxel led to toxicity related death in 1 of 7 mice, but in
the group treated with combined paclitaxel/ABT-737 3
of 8 animals died in the first treatment cycle and the
remaining 5 during the second. Histological analysis of
liver tissue after combination treatment revealed multi-
ple piknotic cell nuclei as a sign of induction of apopto-
sis also in healthy tissues instead of direct hepatic
toxicity [40]. However, these local changes were unlikely
to cause death exclusively. We assume that other tissues
such as bowel and brain might have been affected, and
will be assessed in further optimization studies. As the
animals showed regeneration of body weight between
the two cycles, elongation of the treatment free interval
might reduce adverse side effects. Toxicity due to com-
bination treatment may also be reduced by using second
generation orally bioavailable BH3 mimetics, such as
ABT-263 [41]. ABT-263 might further increase additive
effects of combination treatment in HB cells in vivo
compared to ABT-737. In this coherency, reduction of
paclitaxel dosages might become usable with maintai-
nance of anti-tumour activity and synchronous lowering
of side effects.
Conclusions
The primary goal of current chemotherapy in HB is
reduction of tumour volume to enable complete surgical
resection. Our results have proven optimization of
chemotherapy by using modulators of apoptosis.
However, improvement of pharmacological properties of
both, paclitaxel and ABT-737, seems essential to reduce
toxic side effects. Sensitising HB cells to apoptosis may
restore sensitivity of resistant HB to established thera-
peutic regimens.
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